Chen, William C. W. http://orcid.org/0000-0002-6891-3557
Gaidukov, Leonid
Lai, Yong
Wu, Ming-Ru
Cao, Jicong
Gutbrod, Michael J.
Choi, Gigi C. G. http://orcid.org/0000-0003-2774-9188
Utomo, Rachel P.
Chen, Ying-Chou
Wroblewska, Liliana
Kellis, Manolis http://orcid.org/0000-0001-7113-9630
Zhang, Lin
Weiss, Ron http://orcid.org/0000-0003-0396-2443
Lu, Timothy K.
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Heart, Lung, and Blood Institute (5T32HL007208)
U.S. Department of Defense (W81XWH2110089)
University of South Dakota, Sanford School of Medicine New Faculty Startup Fund
Pfizer-MIT RCA Synthetic Biology Program (CHO2.0 and Precision Post-Translational Modification).
Article History
Received: 1 April 2021
Accepted: 13 September 2022
First Online: 18 October 2022
Competing interests
: T.K.L. is a co-founder of Senti Biosciences, Synlogic, Engine Biosciences, Tango Therapeutics, Corvium, BiomX, Eligo Biosciences, OpenProtein.AI, Bota.Bio. T.K.L. also holds financial interests in nest.bio, Ampliphi, IndieBio, Cognito Health, Quark Biosciences, Personal Genomics, Thryve, Lexent Bio, MitoLab, Vulcan, Serotiny, and Provectus Algae. All other authors declare no competing interests.